Mark Pruzanski - Net Worth and Insider Trading

Mark Pruzanski Net Worth

The estimated net worth of Mark Pruzanski is at least $11 Million dollars as of 2024-04-19. Mark Pruzanski is the President & CEO of Intercept Pharmaceuticals Inc and owns about 566,829 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $11 Million. Details can be seen in Mark Pruzanski's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Pruzanski has not made any transactions after 2019-12-31 and currently still holds the listed stock(s).

Transaction Summary of Mark Pruzanski

To

Mark Pruzanski Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Pruzanski owns 2 companies in total, including Intercept Pharmaceuticals Inc (ICPT) , and Equillium Inc (EQ) .

Click here to see the complete history of Mark Pruzanski’s form 4 insider trades.

Insider Ownership Summary of Mark Pruzanski

Ticker Comapny Transaction Date Type of Owner
ICPT Intercept Pharmaceuticals Inc 2019-12-31 director & President & CEO
EQ Equillium Inc 2018-10-11 director

Mark Pruzanski Latest Holdings Summary

Mark Pruzanski currently owns a total of 1 stock. Mark Pruzanski owns 566,829 shares of Intercept Pharmaceuticals Inc (ICPT) as of December 31, 2019, with a value of $11 Million.

Latest Holdings of Mark Pruzanski

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ICPT Intercept Pharmaceuticals Inc 2019-12-31 566,829 19.00 10,769,751

Holding Weightings of Mark Pruzanski


Mark Pruzanski Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Pruzanski has made a total of 3 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Intercept Pharmaceuticals Inc is the sale of 100 shares on December 31, 2019, which brought Mark Pruzanski around $12,500.

Insider Trading History of Mark Pruzanski

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Pruzanski Trading Performance

GuruFocus tracks the stock performance after each of Mark Pruzanski's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Pruzanski is 36.02%. GuruFocus also compares Mark Pruzanski's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Pruzanski within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Pruzanski's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Pruzanski

Average Return

70.98%

Average return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.99 36.02 54.45 70.98 0.01 -31.56
Relative Return to S&P 500(%) 0.75 29.48 44.23 60.84 -3.31 -48.02

Mark Pruzanski Ownership Network

Ownership Network List of Mark Pruzanski

No Data

Ownership Network Relation of Mark Pruzanski


Mark Pruzanski Owned Company Details

What does Intercept Pharmaceuticals Inc do?

Who are the key executives at Intercept Pharmaceuticals Inc?

Mark Pruzanski is the director & President & CEO of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

Mark Pruzanski Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Pruzanski. You might contact Mark Pruzanski via mailing address: C/o Intercept Pharmaceuticals, Inc., 18 Desbrosses St., New York Ny 10013.

Discussions on Mark Pruzanski

No discussions yet.